Phase II study of sorafenib in patients with relapsed or refractory lymphoma
British Journal of Haematology, 05/11/2012
Guidetti A et al. – Compared with patients with progressive disease (PD), responsive patients had significantly higher baseline levels of extracellular signal–regulated kinase phosphorylation and autophagy and presented a significant reduction of these parameters after 1 month of therapy. Sorafenib was well tolerated and had a clinical activity that warrants development of combination regimens.